Document is current

Article History

Accepted: 29 July 2022

First Online: 17 September 2022

Declarations

:

: This study was sponsored by Incyte Corporation (Wilmington, DE, USA).

: Ghassan K. Abou-Alfa has received research grants from Agios, Arcus, AstraZeneca, Bayer, BioNTech, BMS, Celgene, Flatiron, Genentech/Roche, GeoScience, Incyte Corporation, Polaris, Puma, QED, SillaJen, and Yiviva; and acted as a consultant for Agios, Alnylam, AstraZeneca, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Eisai, Eli Lilly and Company, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte Corporation, Ipsen, Legend Biotech, Loxo, Merck, MINA, QED, Rafael, Redhill, Silenseed, Sillajen, Sobi, Surface Oncology, Therabionics, twoXAR, Vector, and Yiviva. Nikolaus Schultz, Amin Yaqubie, and Brittanie Millang report no conflicts of interest. Kristen Bibeau, Haobo Ren, and Luis Féliz report employment by and stock ownership in Incyte Corporation.

: Ethics approval was not required for this non-interventional retrospective study.

: Not applicable.

: Not applicable.

: All data generated or analyzed during this study are included in this article and/or its supplementary material files. Further inquiries can be directed to the corresponding author.

: Not applicable.

: All authors contributed to the conceptualization and study design, data collection, analysis and interpretation, and drafting/editing of the manuscript.